Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Annette Hasenburg Prof., Dr, med
Annette Hasenburg Prof., Dr, med Advisory Board
Guru Sonpavde MD
Guru P. Sonpavde MD Advisory Board
Barbara Burtness MD
Barbara Burtness MD Advisory Board
See All Experts
story of the week
Published in Oncology

Journal Scan / Research · June 26, 2014

Upregulation of Serum CA19-9 Prior to Pancreatic Cancer Diagnosis

Clinical Cancer Research

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Axel Grothey MD

Clinical Cancer Research
Serum CA19-9 Is Significantly Up-Regulated Up to 2 Years Prior to Diagnosis With Pancreatic Cancer: Implications for Early Disease Detection
Clin. Cancer Res 2014 Jun 17;[EPub Ahead of Print], DP O'Brien, NS Sandanayake, C Jenkinson, A Gentry-Maharaj, S Apostolidou, EO Fourkala, S Camuzeaux, O Blyuss, R Gunu, A Dawnay, A Zaikin, RC Smith, I Jacobs, U Menon, E Costello, SP Pereira, JF Timms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated